Literature DB >> 12215088

Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment.

Dennis M Robertson1.   

Abstract

OBJECTIVE: To describe the clinical findings in 3 eyes with circumscribed choroidal hemangioma before and after treatment with photodynamic therapy. PATIENTS AND METHODS: In the setting of a tertiary referral center, 2 patients with circumscribed, posteriorly located, choroidal hemangiomas (thicknesses 2.4 and 2.9 mm) contiguous with the superior boundary of the optic nerve and accompanied by serous detachments of the sensory retina extending into the macula were treated with photodynamic therapy using a Zeiss diode laser (692 nm) and a sensitizing dye, verteporfin. A third patient with a circumscribed subfoveal hemangioma (3.9 mm in thickness) and a prominent serous retinal detachment was similarly treated. The tumors were studied with ultrasonography and fluorescein angiography. Visual fields were tested with Goldmann perimetry at follow-up.
RESULTS: Following photodynamic therapy, the serous retinal detachments resolved, and the choroidal hemangioma in each of the 3 eyes regressed to a nonmeasurable thickness within 2 to 5 months. The visual acuity improved from 20/50 to 20/20, 20/150 to 20/20, and 3/200 to 20/200 in the respective cases. Two eyes were treated twice. The tumors have not recurred at follow-up visits from 11 to 16 months. Nerve fiber bundle field defects were not demonstrated with Goldmann field testing.
CONCLUSIONS: Photodynamic therapy seems to be effective in the management of circumscribed choroidal hemangioma. Following photodynamic therapy, the choroidal hemangiomas in 3 eyes were no longer measurable by ultrasonography, and the accompanying serous detachments resolved with improvement in the central visual acuities. Nerve fiber bundle defects were not identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215088     DOI: 10.1001/archopht.120.9.1155

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

Review 1.  The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma.

Authors:  Bernhard Jurklies; Norbert Bornfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-08       Impact factor: 3.117

2.  Combination photodynamic therapy and juxtascleral triamcinolone acetonide for the treatment of a peripapillary choroidal neovascular membrane associated with papilloedema.

Authors:  A Tewari; G K Shah; M S Dhalla; J B Shepherd
Journal:  Br J Ophthalmol       Date:  2006-10       Impact factor: 4.638

3.  Comparison of outcomes between overlapping-spot and single-spot photodynamic therapy for circumscribed choroidal hemangioma.

Authors:  Zhao-An Su; Xia-Jing Tang; Li-Xia Zhang; Xiao-Hong Su
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

4.  Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity.

Authors:  F D Verbraak; R O Schlingemann; M D de Smet; J E E Keunen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02-28       Impact factor: 3.117

Review 5.  Photodynamic therapy of circumscribed choroidal haemangioma.

Authors:  A D Singh; P K Kaiser; J E Sears; M Gupta; P A Rundle; I G Rennie
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

6.  Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy.

Authors:  F D Verbraak; R O Schlingemann; J E E Keunen; M D de Smet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-18       Impact factor: 3.117

7.  Spontaneous exudative retinal detachment in a patient with sturge-weber syndrome after taking arginine, a supplement for erectile dysfunction.

Authors:  Austin Bach; Aaron S Gold; Victor M Villegas; Andrea C Wildner; Fiona J Ehlies; Timothy G Murray
Journal:  Eye Vis (Lond)       Date:  2014-10-22

Review 8.  Circumscribed choroidal hemangioma: An overview of clinical manifestation, diagnosis and management.

Authors:  Mrittika Sen; Santosh G Honavar
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.